These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17079866)

  • 1. KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis.
    Yi EY; Park SY; Song HS; Son MJ; Yi KY; Yoo SE; Kim YJ
    Exp Mol Med; 2006 Oct; 38(5):502-8. PubMed ID: 17079866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of angiogenic attributes by decursin in endothelial cells and ex vivo rat aortic ring angiogenesis model.
    Bhat TA; Moon JS; Lee S; Yim D; Singh RP
    Indian J Exp Biol; 2011 Nov; 49(11):848-56. PubMed ID: 22126016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-angiogenic activity of sesterterpenes; natural product inhibitors of FGF-2-induced angiogenesis.
    Hussain S; Slevin M; Matou S; Ahmed N; Choudhary MI; Ranjit R; West D; Gaffney J
    Angiogenesis; 2008; 11(3):245-56. PubMed ID: 18330714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-angiogenic and anti-tumor apoptotic activities of SJ-8002, a new piperazine derivative.
    Yi EY; Jeong EJ; Song HS; Lee MS; Kang DW; Joo JH; Kwon HS; Lee SH; Park SK; Chung SG; Cho EH; Kim YJ
    Int J Oncol; 2004 Aug; 25(2):365-72. PubMed ID: 15254733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Betaine inhibits in vitro and in vivo angiogenesis through suppression of the NF-κB and Akt signaling pathways.
    Yi EY; Kim YJ
    Int J Oncol; 2012 Nov; 41(5):1879-85. PubMed ID: 22940742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells.
    Mader JS; Smyth D; Marshall J; Hoskin DW
    Am J Pathol; 2006 Nov; 169(5):1753-66. PubMed ID: 17071598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
    Jung MH; Lee SH; Ahn EM; Lee YM
    Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic activity of beta-eudesmol in vitro and in vivo.
    Tsuneki H; Ma EL; Kobayashi S; Sekizaki N; Maekawa K; Sasaoka T; Wang MW; Kimura I
    Eur J Pharmacol; 2005 Apr; 512(2-3):105-15. PubMed ID: 15840394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways.
    Chen ML; Lin YH; Yang CM; Hu ML
    Mol Nutr Food Res; 2012 Jun; 56(6):889-99. PubMed ID: 22707264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fisetin inhibits various attributes of angiogenesis in vitro and in vivo--implications for angioprevention.
    Bhat TA; Nambiar D; Pal A; Agarwal R; Singh RP
    Carcinogenesis; 2012 Feb; 33(2):385-93. PubMed ID: 22139440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
    Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
    Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-angiogenic activity of the flavonoid precursor 4-hydroxychalcone.
    Varinska L; van Wijhe M; Belleri M; Mitola S; Perjesi P; Presta M; Koolwijk P; Ivanova L; Mojzis J
    Eur J Pharmacol; 2012 Sep; 691(1-3):125-33. PubMed ID: 22721615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-angiogenic activity of the purine analog 6-thioguanine.
    Presta M; Belleri M; Vacca A; Ribatti D
    Leukemia; 2002 Aug; 16(8):1490-9. PubMed ID: 12145690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells.
    Yeh CH; Peng HC; Yang RS; Huang TF
    Mol Pharmacol; 2001 May; 59(5):1333-42. PubMed ID: 11306719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway.
    Li M; Wu S; Liu Z; Zhang W; Xu J; Wang Y; Liu J; Zhang D; Tian H; Li Y; Ye W
    Biochem Pharmacol; 2012 May; 83(9):1251-60. PubMed ID: 22305746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor.
    Morais C; Gobe G; Johnson DW; Healy H
    Angiogenesis; 2009; 12(4):365-79. PubMed ID: 19882112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.